{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T19:38:05Z","timestamp":1763926685596,"version":"3.45.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,23]]},"DOI":"10.7759\/cureus.97579","type":"journal-article","created":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T19:34:08Z","timestamp":1763926448000},"source":"Crossref","is-referenced-by-count":0,"title":["The Optic Nerve as a New Diagnostic Frontier in Multiple Sclerosis: How the 2024 McDonald Criteria Leverage Multimodal Evaluation for Earlier Diagnosis"],"prefix":"10.7759","author":[{"given":"Nikolaos","family":"Mitsoudis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Nikolakakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Giantzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Demetrios","family":"Pirounides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Bakirtzis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(22)00200-9","article-title":"Diagnosis and classification of optic neuritis","volume":"21","author":"Petzold A","year":"2022","unstructured":"Petzold A, Fraser CL, Abegg M, et al.. Diagnosis and classification of optic neuritis. Lancet Neurol. 2022, 21:1120-34. 10.1016\/s1474-4422(22)00200-9","journal-title":"Lancet Neurol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(02)08220-x","article-title":"Multiple sclerosis","volume":"359","author":"Compston A","year":"2002","unstructured":"Compston A, Coles A. Multiple sclerosis. Lancet. 2002, 359:1221-31. 10.1016\/s0140-6736(02)08220-x","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/00041327-200112000-00015","article-title":"Optic neuritis: historical aspects","volume":"21","author":"Volpe NJ","year":"2001","unstructured":"Volpe NJ. Optic neuritis: historical aspects. J Neuroophthalmol. 2001, 21:302-9. 10.1097\/00041327-200112000-00015","journal-title":"J Neuroophthalmol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.47795\/NMHO9597","article-title":"Edward Nettleship and optic neuritis","author":"Pearce J","year":"2017","unstructured":"Pearce J. Edward Nettleship and optic neuritis. Adv Clin Neurosci Rehabil. 2017, 10.47795\/NMHO9597","journal-title":"Adv Clin Neurosci Rehabil"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.4.5893.661","article-title":"Visual evoked response in diagnosis of multiple sclerosis","volume":"4","author":"Halliday AM","year":"1973","unstructured":"Halliday AM, McDonald WI, Mushin J. Visual evoked response in diagnosis of multiple sclerosis. Br Med J. 1973, 4:661-4. 10.1136\/bmj.4.5893.661","journal-title":"Br Med J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(25)00270-4","article-title":"Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria","volume":"24","author":"Montalban X","year":"2025","unstructured":"Montalban X, Lebrun-Fr\u00e9nay C, Oh J, et al.. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol. 2025, 24:850-65. 10.1016\/s1474-4422(25)00270-4","journal-title":"Lancet Neurol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(25)00275-3","article-title":"The use of optical coherence tomography and visual evoked potentials in the 2024 McDonald diagnostic criteria for multiple sclerosis","volume":"24","author":"Saidha S","year":"2025","unstructured":"Saidha S, Green AJ, Leocani L, et al.. The use of optical coherence tomography and visual evoked potentials in the 2024 McDonald diagnostic criteria for multiple sclerosis. Lancet Neurol. 2025, 24:880-92. 10.1016\/s1474-4422(25)00275-3","journal-title":"Lancet Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson AJ","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, et al.. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018, 17:162-73. 10.1016\/s1474-4422(17)30470-2","journal-title":"Lancet Neurol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231225848","article-title":"Optic nerve topography in multiple sclerosis diagnostic criteria: existing knowledge and future directions","volume":"30","author":"Vidal-Jordana A","year":"2024","unstructured":"Vidal-Jordana A, Sastre-Garriga J, Tintor\u00e9 M, Rovira \u00c0, Montalban X. Optic nerve topography in multiple sclerosis diagnostic criteria: existing knowledge and future directions. Mult Scler. 2024, 30:139-49. 10.1177\/13524585231225848","journal-title":"Mult Scler"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa458","article-title":"Subclinical anterior optic pathway involvement in early multiple sclerosis and clinically isolated syndromes","volume":"144","author":"Pisa M","year":"2021","unstructured":"Pisa M, Croese T, Dalla Costa G, et al.. Subclinical anterior optic pathway involvement in early multiple sclerosis and clinically isolated syndromes. Brain. 2021, 144:848-62. 10.1093\/brain\/awaa458","journal-title":"Brain"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104216","article-title":"Benefits of early treatment with natalizumab: a real-world study","volume":"68","author":"Ontaneda D","year":"2022","unstructured":"Ontaneda D, Mowry EM, Newsome SD, et al.. Benefits of early treatment with natalizumab: a real-world study. Mult Scler Relat Disord. 2022, 68:104216. 10.1016\/j.msard.2022.104216","journal-title":"Mult Scler Relat Disord"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(25)00304-7","article-title":"2024 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI for the diagnosis of multiple sclerosis","volume":"24","author":"Barkhof F","year":"2025","unstructured":"Barkhof F, Reich DS, Oh J, et al.. 2024 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI for the diagnosis of multiple sclerosis. Lancet Neurol. 2025, 24:866-79. 10.1016\/s1474-4422(25)00304-7","journal-title":"Lancet Neurol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207507","article-title":"Diagnostic performance of adding the optic nerve region assessed by optical coherence tomography to the diagnostic criteria for multiple sclerosis","volume":"101","author":"Bsteh G","year":"2023","unstructured":"Bsteh G, Hegen H, Altmann P, et al.. Diagnostic performance of adding the optic nerve region assessed by optical coherence tomography to the diagnostic criteria for multiple sclerosis. Neurology. 2023, 101:e784-93. 10.1212\/WNL.0000000000207507","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.03.007","article-title":"Optical coherence tomography as a biomarker of neurodegeneration in multiple sclerosis: a review","volume":"22","author":"Alonso R","year":"2018","unstructured":"Alonso R, Gonzalez-Moron D, Garcea O. Optical coherence tomography as a biomarker of neurodegeneration in multiple sclerosis: a review. Mult Scler Relat Disord. 2018, 22:77-82. 10.1016\/j.msard.2018.03.007","journal-title":"Mult Scler Relat Disord"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2025.e42114","article-title":"New optical coherence tomography biomarker for diagnosis of acute optic neuritis in multiple sclerosis","volume":"11","author":"Safwat HM","year":"2025","unstructured":"Safwat HM, Mohamed SA, Elsheshiny AH. New optical coherence tomography biomarker for diagnosis of acute optic neuritis in multiple sclerosis. Heliyon. 2025, 11:e42114. 10.1016\/j.heliyon.2025.e42114","journal-title":"Heliyon"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12651-3","article-title":"Predicting multiple sclerosis disease progression and outcomes with machine learning and MRI-based biomarkers: a review","volume":"271","author":"Yousef H","year":"2024","unstructured":"Yousef H, Malagurski Tortei B, Castiglione F. Predicting multiple sclerosis disease progression and outcomes with machine learning and MRI-based biomarkers: a review. J Neurol. 2024, 271:6543-72. 10.1007\/s00415-024-12651-3","journal-title":"J Neurol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)32346-2","article-title":"Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial","volume":"390","author":"Green AJ","year":"2017","unstructured":"Green AJ, Gelfand JM, Cree BA, et al.. Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Lancet. 2017, 390:2481-9. 10.1016\/s0140-6736(17)32346-2","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-32278-0","article-title":"A phase 1 randomized study on the safety and pharmacokinetics of OCS-05, a neuroprotective disease modifying treatment for acute optic neuritis and multiple sclerosis","volume":"13","author":"Villoslada P","year":"2023","unstructured":"Villoslada P, Masso M, Paris S, Hutchings S, Koch A. A phase 1 randomized study on the safety and pharmacokinetics of OCS-05, a neuroprotective disease modifying treatment for acute optic neuritis and multiple sclerosis. Sci Rep. 2023, 13:5099. 10.1038\/s41598-023-32278-0","journal-title":"Sci Rep"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.4103\/ATMR.ATMR_38_25","article-title":"Diagnostic accuracy of optical coherence tomography in patients with optic neuritis","volume":"2","author":"Aljaidi HK","year":"2025","unstructured":"Aljaidi HK, Alorfi Y, Alghannami R, et al.. Diagnostic accuracy of optical coherence tomography in patients with optic neuritis. J Adv Trends Med Res. 2025, 2:138-44. 10.4103\/ATMR.ATMR_38_25","journal-title":"J Adv Trends Med Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-025-01140-4","article-title":"The 2024 revisions of the McDonald criteria pose risk of multiple sclerosis overdiagnosis","author":"Solomon AJ","year":"2025","unstructured":"Solomon AJ, Brodersen JB. The 2024 revisions of the McDonald criteria pose risk of multiple sclerosis overdiagnosis. Nat Rev Neurol. 2025, 10.1038\/s41582-025-01140-4","journal-title":"Nat Rev Neurol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/435687-the-optic-nerve-as-a-new-diagnostic-frontier-in-multiple-sclerosis-how-the-2024-mcdonald-criteria-leverage-multimodal-evaluation-for-earlier-diagnosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T19:34:08Z","timestamp":1763926448000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/435687-the-optic-nerve-as-a-new-diagnostic-frontier-in-multiple-sclerosis-how-the-2024-mcdonald-criteria-leverage-multimodal-evaluation-for-earlier-diagnosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,23]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.97579","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,23]]}}}